Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HOMER2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HOMER2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HOMER2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HOMER2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HOMER2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000189410 | Endometrium | AEH | tissue homeostasis | 50/2100 | 268/18723 | 2.04e-04 | 2.54e-03 | 50 |
GO:00602499 | Endometrium | AEH | anatomical structure homeostasis | 55/2100 | 314/18723 | 5.27e-04 | 5.32e-03 | 55 |
GO:00109597 | Endometrium | AEH | regulation of metal ion transport | 66/2100 | 406/18723 | 1.24e-03 | 1.07e-02 | 66 |
GO:000189415 | Endometrium | EEC | tissue homeostasis | 51/2168 | 268/18723 | 2.34e-04 | 2.75e-03 | 51 |
GO:001095914 | Endometrium | EEC | regulation of metal ion transport | 70/2168 | 406/18723 | 4.12e-04 | 4.35e-03 | 70 |
GO:006024914 | Endometrium | EEC | anatomical structure homeostasis | 56/2168 | 314/18723 | 6.52e-04 | 6.35e-03 | 56 |
GO:0042220 | Liver | NAFLD | response to cocaine | 13/1882 | 55/18723 | 2.64e-03 | 2.42e-02 | 13 |
GO:00432791 | Liver | HCC | response to alkaloid | 62/7958 | 115/18723 | 8.79e-03 | 3.42e-02 | 62 |
GO:00331732 | Prostate | BPH | calcineurin-NFAT signaling cascade | 16/3107 | 43/18723 | 9.26e-04 | 5.91e-03 | 16 |
GO:00708842 | Prostate | BPH | regulation of calcineurin-NFAT signaling cascade | 13/3107 | 34/18723 | 2.06e-03 | 1.16e-02 | 13 |
GO:00480163 | Prostate | BPH | inositol phosphate-mediated signaling | 18/3107 | 55/18723 | 2.50e-03 | 1.34e-02 | 18 |
GO:01060562 | Prostate | BPH | regulation of calcineurin-mediated signaling | 13/3107 | 35/18723 | 2.79e-03 | 1.47e-02 | 13 |
GO:00977202 | Prostate | BPH | calcineurin-mediated signaling | 16/3107 | 48/18723 | 3.45e-03 | 1.77e-02 | 16 |
GO:00326232 | Prostate | BPH | interleukin-2 production | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:00326632 | Prostate | BPH | regulation of interleukin-2 production | 19/3107 | 62/18723 | 4.41e-03 | 2.16e-02 | 19 |
GO:006024910 | Prostate | BPH | anatomical structure homeostasis | 68/3107 | 314/18723 | 1.10e-02 | 4.53e-02 | 68 |
GO:00331731 | Prostate | Tumor | calcineurin-NFAT signaling cascade | 16/3246 | 43/18723 | 1.50e-03 | 9.27e-03 | 16 |
GO:000189416 | Prostate | Tumor | tissue homeostasis | 65/3246 | 268/18723 | 2.39e-03 | 1.35e-02 | 65 |
GO:006024915 | Prostate | Tumor | anatomical structure homeostasis | 74/3246 | 314/18723 | 2.82e-03 | 1.54e-02 | 74 |
GO:00708841 | Prostate | Tumor | regulation of calcineurin-NFAT signaling cascade | 13/3246 | 34/18723 | 3.09e-03 | 1.63e-02 | 13 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HOMER2 | SNV | Missense_Mutation | novel | c.419N>G | p.Gln140Arg | p.Q140R | Q9NSB8 | protein_coding | tolerated(0.58) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HOMER2 | SNV | Missense_Mutation | rs757701596 | c.32N>T | p.Ala11Val | p.A11V | Q9NSB8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HOMER2 | SNV | Missense_Mutation | rs532034212 | c.740N>T | p.Thr247Met | p.T247M | Q9NSB8 | protein_coding | deleterious(0.02) | benign(0.186) | TCGA-AX-A2H7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HOMER2 | SNV | Missense_Mutation | novel | c.981N>C | p.Lys327Asn | p.K327N | Q9NSB8 | protein_coding | deleterious(0.01) | possibly_damaging(0.735) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HOMER2 | SNV | Missense_Mutation | rs764617126 | c.571N>T | p.Arg191Trp | p.R191W | Q9NSB8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
HOMER2 | SNV | Missense_Mutation | rs529437974 | c.916N>T | p.Arg306Cys | p.R306C | Q9NSB8 | protein_coding | deleterious(0) | possibly_damaging(0.487) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
HOMER2 | SNV | Missense_Mutation | novel | c.731N>G | p.Glu244Gly | p.E244G | Q9NSB8 | protein_coding | tolerated(0.11) | possibly_damaging(0.844) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HOMER2 | SNV | Missense_Mutation | rs771494593 | c.445G>A | p.Asp149Asn | p.D149N | Q9NSB8 | protein_coding | deleterious(0.03) | possibly_damaging(0.45) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HOMER2 | SNV | Missense_Mutation | | c.538G>A | p.Val180Met | p.V180M | Q9NSB8 | protein_coding | tolerated(0.24) | possibly_damaging(0.657) | TCGA-D1-A17R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HOMER2 | SNV | Missense_Mutation | rs774130600 | c.154N>A | p.Gly52Arg | p.G52R | Q9NSB8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |